Drug class
Pegylated recombinant human coagulation factor VIII; extended-half-life factor VIII replacement biologic
Mechanism of action
Replaces deficient or dysfunctional coagulation factor VIII, acting as a cofactor for activated factor IX in the intrinsic tenase complex to activate factor X and support thrombin generation and fibrin clot formation.
General use cases
- Treatment and prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency), including perioperative management, under the product-specific JIVI indication; inhibitor status and age criteria apply
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
